Celgene has acquired Gloucester Pharmaceuticals for US$340 million upfront and up to $300 million in milestones. Through the deal, Celgene gains Gloucester's romidepsin (Istodax), a histone ...

Several drugs that inhibit epigenetic writers and ... These include DNA methyltransferase and histone deacetylase (HDAC) inhibitors. Further candidates, including inhibitors of acetyl-lysine ...

Newer treatments target pathways like Delta-like ligand 3, poly-ADP-ribose polymerase, and histone deacetylase to address ...

Those include Onxeo/Acrotech's rival HDAC inhibitor Beleodaq (belinostat) – given an accelerated approval for relapsed PTCL in 2014 – as well as Seagen's antibody-drug conjugate Adcetris ...

Italfarmaco's marketing application for HDAC inhibitor givinostat as a treatment ... The Milan-based drugmaker filed for approval of the drug in the US earlier this year, with a priority review ...

PhD Defense of W.P.J. Cox (UMC Utrecht/Kinderen) ...